Company intelligence / Profile preview
Sanaria Inc.
Rockville, Maryland, United Statessanaria.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Sanaria's PfSPZ Vaccine has shown high efficacy in clinical trials, with protection rates ranging from 41-86% over 18 months without booster doses. The PfSPZ-CVac vaccine demonstrated 100% protection against controlled human malaria infection at three months post-immunization. The newest PfSPZ-LARC2 Vaccine is designed to provide high-level protection with just a single dose and is preparing for first-in-human trials.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Whole-parasite sporozoite vaccinesHuman monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Partnerships
NIHSeattle Children's Research Institute's Center for Global Infectious Disease Research (CGIDR)
Beyond the preview
Go deeper on Sanaria Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanaria Inc..